9 results about "Kidney inflammation" patented technology

According to various aspects of this disclosure, the present disclosure relates to methods for reducing kidney inflammation, reducing kidney fibrosis, reducing oxidative stress in the kidney, preventing or reducing the likelihood of chronic kidney disease (CKD), treating or preventing acute kidney injury (AKI) or treating a kidney disease in a subject in need thereof comprising administering, e.g., intramuscularly, to the subject a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV vector comprises a vector genome comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or a functional fragment thereof and an AAV capsid (e.g., AAV1 serotype), optionally, wherein the subject does not suffer from diabetes.

The invention discloses an ICAM-1 targeting engineered exosome-metal phenol nano-drug as well as a preparation method and application thereof. The nano-drug is composed of an engineered exosome and metal phenol nano-particles, wherein ICAM-1 targeting VHH antibodies are displayed on the surface of the engineered exosome, and the metal phenol nano-particles are encapsulated in the engineered exosome and formed by self-assembly of iron ions and resveratrol. The MPNs are efficiently loaded into the exosome through an electroporation method, and a composite nano delivery system (ICAM (at) Exo (at) MPNs) is constructed. The system has multiple advantages of active targeting of kidney inflammation parts, active oxygen responsive drug release, simulation of antioxidant enzyme activity, regulation and control of macrophage functions and the like. The ICAM (at) Exo (at) MPNs can remarkably relieve kidney crystal deposition, oxidative stress and inflammatory response induced by calcium oxalate, and the protective effect of the ICAM (at) Exo (at) MPNs is related to regulation and control of an SLC1A7 / MerTK signal channel. The invention provides an efficient and safe new strategy for preventing and treating the calcium oxalate kidney injury.

This invention discloses a butyrate prodrug co-assembled with artesunate, its preparation method, and its application in kidney diseases, belonging to the field of biomedical technology. The invention first uses docosahexaenoic acid (DHA) as a hydrophobic framework, coupling it with 2,2'-dithiodiethanol to introduce disulfide bonds, and then grafts butyrate via esterification to obtain a butyrate prodrug. The butyrate prodrug and artesunate self-assemble through non-covalent interactions to obtain a co-assembled drug in nanoparticle form. This nanomedicine possesses excellent long-term in vivo circulation and passive targeted accumulation in the kidneys, and can achieve targeted drug release in response to the high-glutathione microenvironment within lesion cells. The two active ingredients synergistically exert metabolic regulation, anti-inflammatory, and antioxidant effects, inhibiting kidney inflammation and oxidative stress at multiple targets, protecting renal tubular epithelial cells, and effectively intervening in the pathological process of acute kidney injury. Furthermore, this drug has high biosafety, is simple to prepare, and is easy to scale up, showing broad application prospects in the prevention and treatment of kidney diseases.

Provided is use of a complement factor B inhibitor in the preparation of a drug for treating or preventing IgA nephropathy or a disease or condition related thereto. Specifically, provided is use of a compound represented by formula I or a pharmaceutically acceptable salt thereof or a hydrate thereof in the preparation of a drug for treating or preventing IgA nephropathy or a disease or condition related thereto. The drug can effectively reduce creatinine and urea nitrogen levels in patients with IgA nephropathy, reduce renal inflammation and / or fibrosis in patients with IgA nephropathy, and provide a novel, effective and safe option for the treatment of IgA nephropathy.

The invention features methods for the treatment of Alport syndrome using a polypeptide containing an extracellular ActRII variant, such as a polypeptide containing an extracellular ActRII chimera or an extracellular ActRIIB variant. The polypeptide may include an extracellular ActRII chimera or an extracellular ActRIIB variant fused to an Fc domain monomer. Treatment of Alport syndrome with a polypeptide described herein may reduce kidney inflammation, reduce kidney fibrosis, slow disease progression, and / or improve kidney function, which may reduce or delay the need for a kidney transplant or dialysis.

The invention provides application of a composition beneficial to pet kidney health, the composition comprises a yeast extract I, Omega-3 fatty acid, a turmeric extract, a yeast extract II, a green tea extract, a gynostemma pentaphylla extract and glutamine, and the composition is applied to protection of pet kidney health. The yeast extract I contains SAM-e, the turmeric extract contains curcumin, and the yeast extract II contains glutathione. The traditional Chinese medicine composition disclosed by the invention shows a curative effect obviously superior to that of a traditional product such as Shenan capsules in the aspects of reducing renal function indexes, improving pathological changes of kidney tissues, inhibiting expression of related genes of kidney inflammation and the like. Experimental results show that the optimal effects are achieved in five dimensions of oxidative stress, inflammatory response, fat metabolism, safety and mechanism verification, and the effectiveness and safety of the composition are fully proved.

The present disclosure belongs to the technical field of biological medicine, and particularly relates to the application of finerenone in the preparation of a drug for treating hypertensive renal injury. The present disclosure provides the application of finerenone in the preparation of a drug for preventing and / or treating hypertensive renal injury, specifically, by using a deoxycorticosterone acetate-salt-induced hypertensive mouse model and a primary mouse renal tubular epithelial cell-bone marrow-derived macrophage co-culture model, it is first revealed that aldosterone and salt corticosteroid receptor signals mediate cell-to-cell communication by promoting PANX1-dependent ATP release in renal tubular epithelial cells, and then activate macrophage P2X7, activate NLRP3-mediated macrophage pyroptosis, and aggravate the molecular mechanism of aldosterone-driven renal inflammation and fibrosis. The present disclosure also provides the application of a substance targeting a PANX1 / extracellular ATP / P2X7 signal axis in the preparation of a drug for preventing and / or treating hypertensive renal injury.

The application belongs to the technical field of plant lactobacillus, and particularly relates to a plant lactobacillus LPU3 and application of the plant lactobacillus LPU3 in relieving hyperuricemia. The plant lactobacillus LPU3 has the functions of degrading uric acid in vitro, inhibiting xanthine oxidase in vitro, intervening hyperuricemia, inhibiting metabolic enzymes, improving kidney injury caused by hyperuricemia, improving kidney inflammation and oxidative stress caused by hyperuricemia, and improving intestinal flora disorder caused by hyperuricemia.

Positron emission tomography (PET) is a bioimaging technique that relies on positron emitting probes. PET probes can be obtained from a non-labeled probe by a late-stage radiolabelling step with a radionuclide, prior to the injection of the probe to the patient. Because of the short half-life duration of most radionuclides, the radiolabelling step must be rapid. The present invention provides a method allowing the rapid embedding of 68Ga into particles comprising polydopamine. The particles labeled with the method are very stable and are obtained in high yield with a high purity. It has been shown that radiolabeled particles obtained with the method of the invention and functionalized with antibodies were efficient in revealing lung and kidney inflammation via a whole-body PET scan in a LPS-induced sepsis mouse model. Such probes, when they further incorporate magnetic nanoparticles, carry a high potential to improve the diagnosis of inflammation via PET-MRI.